Does the media favor XFOR or ANIX?

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 3 mentions for Anixa Biosciences. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Anixa Biosciences' score of -0.32 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CMPX or ANIX more profitable?

Compass Therapeutics' return on equity of -39.75% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% Anixa Biosciences N/A -71.12% -62.88%

Does the media prefer CMPX or ANIX?

In the previous week, Compass Therapeutics had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Compass Therapeutics and 3 mentions for Anixa Biosciences. Compass Therapeutics' average media sentiment score of 0.52 beat Anixa Biosciences' score of -0.32 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LXEO or ANIX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Anixa Biosciences N/A -71.12% -62.88%

Does the media favor LXEO or ANIX?

In the previous week, Lexeo Therapeutics had 6 more articles in the media than Anixa Biosciences. MarketBeat recorded 9 mentions for Lexeo Therapeutics and 3 mentions for Anixa Biosciences. Lexeo Therapeutics' average media sentiment score of -0.15 beat Anixa Biosciences' score of -0.32 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ANIX or AVIR?

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 159.94%. Given Anixa Biosciences' higher possible upside, equities analysts plainly believe Anixa Biosciences is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is ANIX or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Atea Pharmaceuticals N/A -57.01% -51.49%

Anixa Biosciences (ANIX) Competitors

$3.27 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

ANIX vs. XFOR, CMPX, LXEO, UPB, and AVIR

Should you buy Anixa Biosciences stock or one of its competitors? MarketBeat compares Anixa Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anixa Biosciences include X4 Pharmaceuticals (XFOR), Compass Therapeutics (CMPX), Lexeo Therapeutics (LXEO), Upstream Bio (UPB), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Anixa Biosciences compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

X4 Pharmaceuticals presently has a consensus price target of $9.38, suggesting a potential upside of 127.00%. Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 159.94%. Given Anixa Biosciences' higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

X4 Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Anixa Biosciences' return on equity of -71.12% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences has lower revenue, but higher earnings than X4 Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$9.01M	43.22	-$79.20M	-$4.54	N/A
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 3 mentions for Anixa Biosciences. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Anixa Biosciences' score of -0.32 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

X4 Pharmaceuticals and Anixa Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Compass Therapeutics presently has a consensus target price of $12.25, indicating a potential upside of 439.65%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 159.94%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Compass Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Compass Therapeutics had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Compass Therapeutics and 3 mentions for Anixa Biosciences. Compass Therapeutics' average media sentiment score of 0.52 beat Anixa Biosciences' score of -0.32 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences has lower revenue, but higher earnings than Compass Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	480.95	-$66.49M	-$0.41	N/A
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Compass Therapeutics' return on equity of -39.75% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Anixa Biosciences	N/A	-71.12%	-62.88%

Summary

Compass Therapeutics beats Anixa Biosciences on 12 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Lexeo Therapeutics had 6 more articles in the media than Anixa Biosciences. MarketBeat recorded 9 mentions for Lexeo Therapeutics and 3 mentions for Anixa Biosciences. Lexeo Therapeutics' average media sentiment score of -0.15 beat Anixa Biosciences' score of -0.32 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Lexeo Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 299.79%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 159.94%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anixa Biosciences has higher revenue and earnings than Lexeo Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A

Lexeo Therapeutics' return on equity of -47.48% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Anixa Biosciences	N/A	-71.12%	-62.88%

Summary

Lexeo Therapeutics beats Anixa Biosciences on 11 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

29.1% of Anixa Biosciences shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Anixa Biosciences has lower revenue, but higher earnings than Upstream Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	143.40	-$143.44M	-$2.91	N/A
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A

Upstream Bio presently has a consensus target price of $33.17, indicating a potential upside of 341.63%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 159.94%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Upstream Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Anixa Biosciences had 3 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.32 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Upstream Bio	Neutral
Anixa Biosciences	Neutral

Anixa Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Anixa Biosciences	N/A	-71.12%	-62.88%

Upstream Bio has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

Upstream Bio beats Anixa Biosciences on 9 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Atea Pharmaceuticals?

Anixa Biosciences (NASDAQ:ANIX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Atea Pharmaceuticals' return on equity of -57.01% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Anixa Biosciences has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anixa Biosciences had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.32 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Neutral
Atea Pharmaceuticals	Neutral

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 159.94%. Given Anixa Biosciences' higher possible upside, equities analysts plainly believe Anixa Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Anixa Biosciences has higher revenue and earnings than Atea Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Anixa Biosciences beats Atea Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$111.26M	$3.78B	$7.17B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-10.55	21.61	28.02	24.70
Price / Sales	529.74	342.06	540.72	98.05
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	8.38	8.66	10.96	6.46
Net Income	-$10.93M	$23.81M	$3.57B	$337.01M
7 Day Performance	18.91%	3.39%	2.12%	1.69%
1 Month Performance	31.85%	10.81%	5.25%	3.81%
1 Year Performance	-2.39%	62.61%	33.29%	23.90%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	4.1921 of 5 stars	$3.27 flat	$8.50 +159.9%	-2.4%	$111.26M	$210K	N/A	5	Analyst Forecast High Trading Volume
XFOR X4 Pharmaceuticals	2.8982 of 5 stars	$4.23 +5.2%	$9.38 +121.6%	+110.2%	$379.17M	$35.11M	N/A	80	News Coverage
CMPX Compass Therapeutics	3.1083 of 5 stars	$2.16 +3.8%	$12.91 +497.6%	-18.2%	$374.58M	$850K	N/A	20	News Coverage Analyst Forecast
LXEO Lexeo Therapeutics	1.8281 of 5 stars	$4.81 +1.3%	$18.75 +289.8%	+5.9%	$372.98M	N/A	N/A	58	News Coverage Insider Trade
UPB Upstream Bio	1.5635 of 5 stars	$6.93 +2.7%	$33.17 +378.6%	-32.9%	$367.33M	$2.85M	N/A	38	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. XFOR, CMPX, LXEO, UPB, and AVIR

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Summary

How does Anixa Biosciences compare to Compass Therapeutics?

Summary

How does Anixa Biosciences compare to Lexeo Therapeutics?

Summary

How does Anixa Biosciences compare to Upstream Bio?

Summary

How does Anixa Biosciences compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. XFOR, CMPX, LXEO, UPB, and AVIR

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Do analysts rate XFOR or ANIX?

Which has more risk & volatility, XFOR or ANIX?

Is XFOR or ANIX more profitable?

Which has higher earnings & valuation, XFOR or ANIX?

Does the media favor XFOR or ANIX?

Do insiders & institutionals hold more shares of XFOR or ANIX?

Summary

How does Anixa Biosciences compare to Compass Therapeutics?

Do analysts recommend CMPX or ANIX?

Which has more volatility and risk, CMPX or ANIX?

Does the media prefer CMPX or ANIX?

Which has better earnings and valuation, CMPX or ANIX?

Do institutionals & insiders believe in CMPX or ANIX?

Is CMPX or ANIX more profitable?

Summary

How does Anixa Biosciences compare to Lexeo Therapeutics?

Does the media favor LXEO or ANIX?

Which has more volatility & risk, LXEO or ANIX?

Do analysts recommend LXEO or ANIX?

Do insiders and institutionals believe in LXEO or ANIX?

Which has preferable earnings & valuation, LXEO or ANIX?

Is LXEO or ANIX more profitable?

Summary

How does Anixa Biosciences compare to Upstream Bio?

Do institutionals and insiders hold more shares of UPB or ANIX?

Which has better earnings & valuation, UPB or ANIX?

Do analysts rate UPB or ANIX?

Does the media favor UPB or ANIX?

Is UPB or ANIX more profitable?

Which has more risk and volatility, UPB or ANIX?

Summary

How does Anixa Biosciences compare to Atea Pharmaceuticals?

Is ANIX or AVIR more profitable?

Which has more risk & volatility, ANIX or AVIR?

Do insiders and institutionals hold more shares of ANIX or AVIR?

Does the media refer more to ANIX or AVIR?

Do analysts prefer ANIX or AVIR?

Which has higher valuation and earnings, ANIX or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools